| |
Thursday, March 7, 2024 | 1pm ET / 10am PT Join us for this timely look at the critical role a CDMO’s process development approach can play in shortening development timelines for biotherapeutics. Gain key insights on risk-mitigation strategies, utilizing flexible development platforms, optimizing integration, managing process development, and more. Register now.
|
|
| By Max Bayer Johnson & Johnson is closing a nearly 200,000 square-foot R&D outpost in Brisbane, California, less than 18 months after it opened, according to multiple sources familiar with the decision. |
|
|
|
By Fraiser Kansteiner As part of a cost-cutting and restructuring initiative dubbed "Project Energize," Perrigo expects to trim roughly 6% of its total staff, the company said in a fourth-quarter earnings release Tuesday. Perrigo currently employs around 9,000 staffers, according to its website, meaning nearly 550 employees could lose their jobs as part of the corporate overhaul. |
By Max Bayer While there wasn't another $3 billion private financing in 2023, it doesn't mean there wasn't plenty of money flowing. |
By Gabrielle Masson As Denali Therapeutics narrows in on large molecule biotherapeutics, the company is reorganizing, laying off an undisclosed number of workers and sending some to a new small molecule spinout. |
By Fraiser Kansteiner Teva and Alvotech have braved a long and winding road on the quest to win approval for their biosimilar to AbbVie’s Humira. Now, after multiple manufacturing setbacks, the partners have finally scored their inaugural regulatory nod in the U.S. |
By Andrea Park In the wake of a recent reminder from the FDA that it still has yet to OK any noninvasive devices to measure blood sugar, Know Labs is ramping up its efforts to change that. |
By Conor Hale The spending spree comes alongside Ginkgo’s unveiling of a new technology network that encompasses a list of offerings from more than 25 of the company’s developer partners and previous acquisitions. |
By Angus Liu Even Alexander Hardy, the former Genentech leader who managed the blockbuster hemophilia drug Hemlibra, can’t immediately bend the laggard launch trajectory of BioMarin’s gene therapy Roctavian. |
By Ben Adams It wasn’t supposed to be like this: Eisai and Biogen’s new Alzheimer’s disease drug Leqembi was supposed to be the chosen one after the flop that was Biogen and Eisai’s Aduhelm, but neurologists are voicing “frustration” at core elements of the therapy’s rollout. |
By Zoey Becker As the World Health Organization and others pine for new innovation in antibiotics, a combination option from Venatorx Pharmaceuticals and Melinta Therapeutics won't be able to help out the cause anytime soon as manufacturing issues have led to an FDA rejection. |
By Helen Floersh Mouse data from a new study sponsored in part by Chroma Medicine suggests that epigenetic gene silencing can suppress the target gene for nearly a year, providing new evidence for the lasting effects of epigenetic therapies. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," Editor-in-Chief Ayla Ellison explores the critical issue of maternal mental health in an interview with Dr. Ken Levey, co-founder and CEO of Mother Goose Health. |
|
|---|
|
|
|
Wednesday, March 13, 2024 | 11am ET / 8am PT Extractables and leachables are a hot topic in the pharmaceutical industry today. As single-use systems, devices, and routes of administration evolve, it is important to have a strategy that helps ensure you choose proper equipment and materials, file on time, avoid repeat studies, and more. Save your spot to be a part of this insightful discussion!
|
|
| WhitepaperAmidst rapid change, it is crucial for specialty distributors to maintain a balance of service and quality for manufacturers, ensuring neither is sacrificed. Explore why this balance is paramount for success in the evolving landscape of pharma. Sponsored by: BioCare |
| Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperSupercharge Your Field Deployment in 2024 with Engaging, Clinically-Oriented and Influential FRMs, MSLs, NAMs and CNEs. Krista Pinto, President, Field Deployment, EVERSANA |
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
